Compared with patients with only chronic obstructive pulmonary disease (COPD), patients with COPD and anxiety and/or depression had increased clinical and economic burden.
Japan’s Eisai aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later this year, but expects growth to accelerate significantly in 2025 as diagnosis methods change, a company spokesperson told Reuters. More convenient Alzheimer's blood tests expected to be ready then could help Eisai reach a bigger share of China’s estimated 17 million people with early-stage disease, the spokesperson said. “China is one of the fastest-aging countries in the world and is one of the most important countries in the area of Alzheimer’s disease for Eisai,” a company spokesperson said.
Japan’s Eisai
aims to roll out its groundbreaking Alzheimer’s drug
Leqembi to 1,500 people in China later this year, but expects
growth to accelerate significantly in 2025 as diagnosis.
Evaluating relationship between two functional GAS5 polymorphisms (rs145204276 and rs55829688) and the risk for renal cell carcinoma in Han Chinese population
广东医疗防护纺织品产业链基本健全 2020年口罩产量居全国第一_南方网 southcn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from southcn.com Daily Mail and Mail on Sunday newspapers.